(R)-3-Amino-5-phenylpentanoic acid hydrochloride
Need Assistance?
  • US & Canada:
    +
  • UK: +

(R)-3-Amino-5-phenylpentanoic acid hydrochloride

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
β−Amino acids
Catalog number
BAT-006626
CAS number
331846-98-1
Molecular Formula
C11H16ClNO2
Molecular Weight
229.70
(R)-3-Amino-5-phenylpentanoic acid hydrochloride
IUPAC Name
(3R)-3-amino-5-phenylpentanoic acid;hydrochloride
Synonyms
H-D-Hph-(C#CH2)OH HCl; H-D-Phe(#CH2,C#CH2)-OH HCl
Related CAS
147228-37-3 (free base)
Storage
Store at 2-8°C
InChI
InChI=1S/C11H15NO2.ClH/c12-10(8-11(13)14)7-6-9-4-2-1-3-5-9;/h1-5,10H,6-8,12H2,(H,13,14);1H/t10-;/m1./s1
InChI Key
GSSXWQCQDYAEFF-HNCPQSOCSA-N
Canonical SMILES
C1=CC=C(C=C1)CCC(CC(=O)O)N.Cl
2. The Role of Bile Acids in Chronic Diarrhea
Michael Camilleri, Priya Vijayvargiya Am J Gastroenterol. 2020 Oct;115(10):1596-1603. doi: 10.14309/ajg.0000000000000696.
Bile acids (BAs) are the central signals in enterohepatic communication, and they also integrate microbiota-derived signals into enterohepatic signaling. The tissue distribution and signaling pathways activated by BAs through natural receptors, farsenoid X receptor and G protein-coupled BA receptor 1 (GPBAR1, also known as Takeda G-coupled receptor 5), have led to a greater understanding of the mechanisms and potential therapeutic agents. BA diarrhea is most commonly encountered in ileal resection or disease, in idiopathic disorders (with presentation similar to functional diarrhea or irritable bowel syndrome with diarrhea), and in association with malabsorption such as chronic pancreatitis or celiac disease. Diagnosis of BA diarrhea is based on Se-homocholic acid taurine retention, 48-hour fecal BA excretion, or serum 7αC4; the latter being a marker of hepatic BA synthesis. BA diarrhea tends to be associated with higher body mass index, increased stool weight and stool fat, and acceleration of colonic transit. Biochemical markers of increased BA synthesis or excretion are available through reference laboratories. Current treatment of BA diarrhea is based on BA sequestrants, and, in the future, it is anticipated that farsenoid X receptor agonists may also be effective. The optimal conditions for an empiric trial with BA sequestrants as a diagnostic test are still unclear. However, such therapeutic trials are widely used in clinical practice. Some national guidelines recommend definitive diagnosis of BA diarrhea over empirical trial.
3. Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics
Ysabella Z A Van Sebille, Romany Stansborough, Hannah R Wardill, Emma Bateman, Rachel J Gibson, Dorothy M Keefe Curr Oncol Rep. 2015 Nov;17(11):50. doi: 10.1007/s11912-015-0474-9.
Chemotherapy-induced mucositis is a common condition caused by the breakdown of the mucosal barrier. Symptoms can include pain, vomiting and diarrhoea, which can often necessitate chemotherapy treatment breaks or dose reductions, thus compromising survival outcomes. Despite the significant impact of mucositis, there are currently limited clinically effective pharmacological therapies for the pathology. New emerging areas of research have been proposed to play key roles in the development of mucositis, providing rationale for potential new therapeutics for the prevention, treatment or management of chemotherapy-induced mucositis. This review aims to address these new areas of research and to comment on the therapeutics arising from them.
Online Inquiry
Verification code
Inquiry Basket